RLAY Stock Risk & Deep Value Analysis
Relay Therapeutics Inc
DVR Score
out of 10
What You Need to Know About RLAY Stock
We analyzed Relay Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RLAY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
RLAY Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is clinical trial failure for zovegalisib (RLY-2608), the flagship asset. Negative data or safety concerns in Phase 3 could halt development, leading to a substantial pipeline setback and significant stock devaluation. This would necessitate a major pivot or capital raise under unfavorable terms.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Continued negative free cash flow forecast through 2028 indicates ongoing capital dependency.
- ⚠
Lack of explicit balance sheet cash position in the provided real-time data, raising uncertainty about liquidity runway.
Upcoming Risk Events
- 📅
Negative or inconclusive Phase 3 Zovegalisib clinical trial results
- 📅
Delay or rejection of RLY-4008 NDA by FDA
- 📅
Significant dilutive capital raise due to cash burn
When to Reconsider
- 🚪
Negative or inconclusive data from Phase 3 Zovegalisib trials.
- 🚪
RLY-4008 NDA rejection or significant delays.
- 🚪
Major dilutive equity raise (e.g., >20% increase in share count without substantial de-risking).
Unlock RLAY Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Relay Therapeutics is a high-growth, high-risk biotech poised for significant re-rating driven by its differentiated Dynamo computational drug discovery platform and a maturing pipeline. The company has recently achieved its first revenue milestone via an out-licensed asset (RLY-4008) and demonstrated promising Phase 1/2 clinical data for its lead asset, zovegalisib (RLY-2608), which is now in Phase 3. With strong institutional backing and clear upcoming catalysts, Relay has a compelling path to becoming a market leader in precision oncology, justifying its 10x growth potential.
Is RLAY Stock Undervalued?
Unlock the full AI analysis for RLAY
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
RLAY Price Targets & Strategy
12-Month Target
$22.50
Bull Case
$45.00
Bear Case
$8.00
Valuation Basis
Based on 0.8x estimated peak sales multiple for flagship product zovegalisib, adjusted for probability of success.
Entry Strategy
Dollar-cost average on dips towards the $12.50-$14.00 range (recent support and analyst targets).
Exit Strategy
Take 50% profit at $22.50-$25.00; consider full exit if clinical setbacks occur or if cash burn accelerates without mitigation.
Portfolio Allocation
10% for aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is RLAY Financially Healthy?
Valuation
P/E Ratio
-8.79
PEG Ratio
-0.10
Price/Book
3.00
Price/Sales
52.70
Profitability
Return on Equity
-41.12%
EPS
$-1.75
Balance Sheet
Total Debt
$33.33M
Cash & Equivalents
$596.43M
Cash Flow
EBITDA
-$320.50M
Other
Beta (Volatility)
1.57
Does RLAY Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The Dynamo platform's ability to generate novel, first-in-class assets provides a significant lead and patent protection, offering durability for 10-20 years if pipeline success continues.
Moat Erosion Risks
- •Competitors developing superior computational platforms or more effective drugs.
- •Patent expiry or challenges for key compounds.
- •Clinical trial failures undermining the platform's perceived value.
RLAY Competitive Moat Analysis
Sign up to see competitive advantages
RLAY Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish (stock jumped 16.4% recently on robust trading volume, indicating strong retail interest).
Institutional Sentiment
Positive (H.C. Wainwright raised price target to $19, Oppenheimer reiterated Outperform, significant ~$11.86M purchase by Casdin Capital).
Insider Activity (Form 4)
Casdin Capital purchased 1,662,193 shares for ~$11.86M on February 17, 2026. No CEO/CFO Form 4 filings disclosed in the last 90 days.
Options Flow
Normal options activity
Earnings Intelligence
Next Earnings
Estimated May 2026
Surprise Probability
Medium
Historical Earnings Pattern
Not enough historical earnings data with revenue to establish a clear pattern; however, recent clinical data announcements have driven significant stock surges.
Key Metrics to Watch
Competitive Position
Top Competitor
Not explicitly provided in research for direct comparison.
Market Share Trend
Gaining (first-ever revenue, first-in-class PI3Kα inhibitor potential).
Valuation vs Peers
Likely trades at a premium given its early-stage, innovative platform, and first-in-class pipeline potential; specific multiples not available for comparison.
Competitive Advantages
- •Proprietary Dynamo computational drug discovery platform.
- •First-in-class pan-mutant selective PI3Kα inhibitor (zovegalisib) in Phase 3.
- •Differentiated precision oncology approach.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive RLAY Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated May 2026)
- •Initial clinical data on Zovegalisib vascular anomalies (May 19-22, 2026 at ISSVA World Congress)
- •RLY-4008 NDA approval decision by FDA
Medium-Term (6-18 months)
- •Progress updates from Phase 3 ReDiscover-2 trial for Zovegalisib
- •Initial commercialization/royalties from RLY-4008 (post-approval)
- •Further pipeline updates (RLY-8161, NRAS program)
Long-Term (18+ months)
- •Zovegalisib market penetration in HR+/HER2- metastatic breast cancer and vascular anomalies
- •Expansion of Dynamo platform into new therapeutic areas
- •Additional licensing deals or internal commercialization of pipeline assets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for RLAY?
- ✓
Positive updates from Phase 3 Zovegalisib trials (ReDiscover-2).
- ✓
Acceleration in revenue growth and clear path to profitability.
- ✓
Confirmation of adequate cash runway or non-dilutive financing.
Bull Case Analysis
See what could go right with Premium
Competing with RLAY
See how Relay Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Relay Therapeutics Inc RLAY | $2.6B | 8.9 | -8.8 | $8.4M | 0.0% | 0.0% | |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Relay Therapeutics Inc Makes Money
Relay Therapeutics is a biotechnology company focused on discovering and developing precision medicines, primarily in oncology, using its proprietary computational drug discovery platform called Dynamo. Instead of making money from selling approved drugs directly, it currently generates revenue through licensing its developed drug candidates to larger pharmaceutical companies, receiving upfront payments and potential future royalties upon drug approval and sales. Its long-term goal is to bring its own drugs to market, leveraging its platform to rapidly identify and advance novel therapies.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Relay Therapeutics Inc (RLAY)?
As of April 9, 2026, Relay Therapeutics Inc has a DVR Score of 8.9 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Relay Therapeutics Inc?
Relay Therapeutics Inc's market capitalization is approximately $2.6B..
What is the risk level for RLAY stock?
Our analysis rates Relay Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of RLAY?
Relay Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -8.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Relay Therapeutics Inc's revenue growing?
Relay Therapeutics Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is RLAY stock profitable?
Relay Therapeutics Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the RLAY DVR analysis updated?
Our AI-powered analysis of Relay Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 9, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RLAY (Relay Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.